Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

被引:527
作者
Imai, C
Iwamoto, S
Campana, D
机构
[1] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[3] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA
关键词
D O I
10.1182/blood-2004-12-4797
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Natural killer (NK) cells hold promise for improving the therapeutic potential of allogeneic hematopoietic transplantation, but their effectiveness is limited by inhibitory HLA types. We sought to overcome this intrinsic resistance by transducing CD56(+)CD3(-) NK cells with chimeric receptors directed against CD19, a molecule widely expressed by malignant B cells. An abundance of NK cells for transduction was secured by culturing peripheral blood mononuclear cells with K562 cells expressing the NK-stimulatory molecules 4-1BB ligand and interleukin 15, which yielded a median greater than 1000-fold expansion of CD56(+)CD3(-) cells at 3 weeks of culture, without T-lymphocyte expansion. Expression of anti-CD19 receptors linked to CD3 xi overcame NK resistance and markedly enhanced NK-cell-mediated killing of leukemic cells. This result was significantly improved by adding the 4-1 BB costimulatory molecule to the chimeric anti-CD19-CD3 xi receptor; the cytotoxicity produced by NK cells expressing this construct uniformly exceeded that of NK cells whose signaling receptors lacked 4-1BB, even when natural cytotoxicity was apparent. Addition of 4-1 BB was also associated with increased cell activation and production of interferon gamma and granulocyte-macrophage colony-stimulating factor. Our findings indicate that enforced expression of signaling receptors by NK cells might circumvent inhibitory signals, providing a novel means to enhance the effectiveness of allogeneic stem cell transplantation.
引用
收藏
页码:376 / 383
页数:8
相关论文
共 70 条
[51]   Childhood acute lymphoblastic leukaemia - current status and future perspectives [J].
Pui, CH ;
Campana, D ;
Evans, WE .
LANCET ONCOLOGY, 2001, 2 (10) :597-607
[52]  
Roberts MR, 1998, J IMMUNOL, V161, P375
[53]  
Robertson MJ, 1997, NAT IMMUN, V15, P213
[54]   USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION [J].
ROONEY, CM ;
SMITH, CA ;
NG, CYC ;
LOFTIN, S ;
LI, CF ;
KRANCE, RA ;
BRENNER, MK ;
HESLOP, HE .
LANCET, 1995, 345 (8941) :9-13
[55]   Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants [J].
Ruggeri, L ;
Capanni, M ;
Urbani, E ;
Perruccio, K ;
Shlomchik, WD ;
Tosti, A ;
Posati, S ;
Rogaia, D ;
Frassoni, F ;
Aversa, F ;
Martelli, MF ;
Velardi, A .
SCIENCE, 2002, 295 (5562) :2097-2100
[56]   Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation [J].
Ruggeri, L ;
Capanni, M ;
Casucci, M ;
Volpi, I ;
Tosti, A ;
Perruccio, K ;
Urbani, E ;
Negrin, RS ;
Martelli, MF ;
Velardi, A .
BLOOD, 1999, 94 (01) :333-339
[57]   Targeting tumours with genetically enhanced T lymphocytes [J].
Sadelain, M ;
Rivière, I ;
Brentjens, R .
NATURE REVIEWS CANCER, 2003, 3 (01) :35-45
[58]   Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo [J].
Schirrmann, T ;
Pecher, G .
CANCER GENE THERAPY, 2002, 9 (04) :390-398
[59]   Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors [J].
Schroers, R ;
Hildebrandt, Y ;
Hasenkamp, J ;
Glass, B ;
Lieber, A ;
Wulf, G ;
Piesche, M .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (06) :536-546
[60]   Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation [J].
Slavin, S ;
Naparstek, E ;
Nagler, A ;
Ackerstein, A ;
Samuel, S ;
Kapelushnik, J ;
Brautbar, C ;
Or, R .
BLOOD, 1996, 87 (06) :2195-2204